Physician profile
William W King
NPI 1437105327
$4,174.14
in general payments reported to CMS, 2019-2025
30 companies · $698 in 2025
The $698 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $525 · 2020: $277 · 2021: $465 · 2022: $833 · 2023: $693 · 2024: $682 · 2025: $698.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,052 · Education: $22.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,051.89 |
| Education | $22.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,707.24 | 2019-2025 | |
| Pfizer INC. | $300.85 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $276.02 | 2019-2022 | |
| Boston Scientific Corporation | $273.69 | 2020-2023 | Axios, Exalt Model D |
| E.R. Squibb & Sons, L.L.C. | $199.33 | 2021 | |
| Medtronic, INC. | $169.12 | 2022-2024 | Interstim |
| Gilead Sciences, INC. | $159.46 | 2019-2023 | |
| Madrigal Pharmaceuticals | $144.35 | 2025 | Rezdiffra |
| Celgene Corporation | $130.45 | 2022-2023 | Zeposia |
| Pentax of America, INC. | $125.73 | 2021-2024 | Pentax Medical, C2 Cryoballoon, Inspira |
| Janssen Biotech, INC. | $99.48 | 2019-2024 | Stelara |
| Ferring Pharmaceuticals INC. | $92.24 | 2024 | Rebyota |
| Ironwood Pharmaceuticals, INC | $51.75 | 2021-2022 | |
| Ardelyx, INC. | $47.09 | 2023-2025 | Ibsrela |
| Nestle Healthcare Nutrition INC. | $46.08 | 2021-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $45.37 | 2019-2024 | Entyvio |
| Cook Medical LLC | $42.76 | 2019-2025 | Hemospray |
| Daiichi Sankyo INC. | $40.46 | 2022 | |
| Aimmune Therapeutics, INC. | $39.80 | 2025 | Zenpep |
| Intercept Pharmaceuticals, INC. | $36.01 | 2024 | |
| Janssen Pharmaceuticals, INC | $27.09 | 2019 | |
| Genzyme Corporation | $22.96 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $22.16 | 2023 | Dupixent |
| Micro-Tech Endoscopy USA, INC. | $16.89 | 2022 | |
| Ucb, INC. | $14.64 | 2019 | |
| Allergan, INC. | $12.40 | 2020 | |
| Intra-Sana Laboratories | $12.33 | 2021 | |
| Merck Sharp & Dohme LLC | $12.22 | 2022 | |
| Phathom Pharmaceuticals, INC. | $6.17 | 2025 | Voquezna |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.